Emcure Pharmaceuticals
Working at Emcure Pharmaceuticals
Company Summary
Overall Rating

Critically rated for
Promotions, Job security, Work satisfaction
Work Policy




Top Employees Benefits
About Emcure Pharmaceuticals
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
With 350+ brands, five R&D centers and 13 manufacturing facilities established across the country, we have ensured a strong presence not just in India but also outside India with a wide network across 70+ countries. Our API facilities ensures that our supply chain is vertically integrated providing flexibility over control of manufacturing. We have cemented strategic global partnerships that are a result of alliances with local and multi-national companies which are at the helm of leadership in key therapeutic areas. The key objective of our widespread presence across markets is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.
Emcure Pharmaceuticals Ratings
Overall Rating
Category Ratings
Salary
Skill development
Work-life balance
Company culture
Work satisfaction
Job security
Promotions
Work Policy at Emcure Pharmaceuticals
Emcure Pharmaceuticals Reviews
Top mentions in Emcure Pharmaceuticals Reviews
Compare Emcure Pharmaceuticals with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 3.7/5 based on 1.9k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | No highly rated category | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | Job security Promotions Work satisfaction | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 82% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 3.5 Good rated by 123 women | 4.0 Good rated by 442 women | 4.1 Good rated by 681 women | - no rating available |
Rating by Men Employees | 3.7 Good rated by 1.7k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.2 Average | 3.8 Good | 3.7 Good | 4.0 Good |
Emcure Pharmaceuticals Salaries
Officer
Production Officer
Territory Manager
Area Business Manager
Regional Manager
Senior Research Fellow
Key Account Manager
Technical Assistant
QC Officer
Medical Representative
Emcure Pharmaceuticals Interview Questions
Interview questions by designation
Top Emcure Pharmaceuticals interview questions and answers
Emcure Pharmaceuticals Jobs
Emcure Pharmaceuticals News
Stocks that will see action today: February 27, 2025
- B Santhanam, CEO of Saint-Gobain Asia Pacific and Chairman of Saint-Gobain India, announced retirement after over four decades with the company.
- Wipro to invest $200 million in Wipro Ventures to support technology start-ups, accelerating funding for early to mid-stage companies.
- Star Health expands Home Health Care to 100 locations, covering 85% of its customer base with doorstep medical care service.
- Assam Government initiates ropeway project with GR Infraprojects, with a proposed investment of ₹270 crore.
- Mastek secures contracts worth $85 million over 2 years from a UK public service department for digital transformation services.
- Zydus Lifesciences introduces vaccine for protection against a new strain of influenza virus, offering protection against four virus strains.
- IndusInd Bank receives ₹21.62 crore demand notice from tax authorities for alleged GST short payment.
- NGL Fine-Chem settles shareholding disclosure violation case with SEBI by paying ₹92.21 lakh along with promoters.
- SEBI imposes ₹5.05 crore penalty on Indian Clearing Corporation Ltd for non-compliance with cyber security and disaster recovery framework.
- Emcure Pharmaceuticals receives two observations from USFDA after cGMP inspection of its Pune-based API manufacturing facility.

Emcure Pharmaceuticals reports strong Q2FY25 with 20% revenue growth and 38% PAT growth
- Emcure Pharmaceuticals reported strong Q2FY25 with 20% revenue growth and 38% PAT growth
- Domestic sales reached ₹933 crore, reflecting a 15.4% y-o-y growth
- EBITDA increased by 26.1% y-o-y with EBITDA margins at 20.8%
- Profit After Tax (PAT) for the quarter stood at ₹202 crore, marking a 38.2% y-o-y growth

Emcure Pharmaceuticals reports strong Q2FY25 with 20% revenue growth and 38% PAT growth
- Emcure Pharmaceuticals reported strong Q2FY25 with 20% revenue growth and 38% PAT growth.
- Domestic sales reached ₹933 crore, reflecting a 15.4% YoY growth.
- EBITDA increased by 26.1% YoY, with EBITDA margins improving to 20.8%.
- Profit After Tax (PAT) for the quarter stood at ₹202 crore, marking a 38.2% YoY growth.

Emcure Pharmaceuticals Subsidiaries
Gennova Biopharmaceuticals
Compare Emcure Pharmaceuticals with




















Contribute & help others!
Companies Similar to Emcure Pharmaceuticals












Emcure Pharmaceuticals FAQs
Reviews
Interviews
Salaries
Users/Month